TY - JOUR
T1 - Core elements of epilepsy diagnosis and management
T2 - Expert consensus from the Leadership in Epilepsy, Advocacy, and Development (LEAD) faculty
AU - Glauser, Tracy A.
AU - Sankar, Raman
AU - Bainbridge, Jacquelyn
AU - Bebin, Martina
AU - Benbadis, Selim R.
AU - Cantrell, Deborah T.C.
AU - Faught, R. Edward
AU - Gruenthal, Michael
AU - Hershkowitz, Laura L.
AU - Holmes, Gregory L.
AU - Husain, Aatif M.
AU - Labiner, David M.
AU - Montouris, Georgia
AU - Naritoku, Dean K.
AU - Olson, Barbara J.
AU - Pellock, John M.
AU - Penovich, Patricia E.
AU - Privitera, Michael D.
AU - Ramsay, R. Eugene
AU - Rho, Jong M.
AU - Richards, Karen C.
AU - Rosenfeld, William E.
AU - Slater, Jeremy D.
AU - Smith, Michael C.
AU - Spitz, Mark C.
AU - Stern, John M.
AU - Vossler, David
AU - Wheless, James W.
N1 - Funding Information:
Declaration of interest: The publication of these consensus views is sponsored by Ortho-McNeil Neurologics, a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. The members of the LEAD faculty have all received honoraria from Ortho-McNeil Neurologics, and the final questionnaire developed by the LEAD faculty review process was reviewed by the sponsor. The consensus results were tabulated with assistance from Health Learning Systems, and the data analysis was conducted independently by members the LEAD faculty. Editorial support and preparation of an initial draft of these consensus findings was provided by Health Learning Systems, and Ortho-McNeil Neurologics reviewed the final manuscript submitted by the LEAD authors. T.A.G. has received grant/ research support from the NIH; is on the speakers’ bureau for Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and UCB Pharma. He is a consultant for Eisai, Ortho-McNeil Neurologics and UCB Pharma. R.S. is a member of the speakers’ bureau for Cyberonics, GlaxoSmithKline, Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and UCB Pharma, and Valeant; and is a consultant for Cyberonics, Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and UCB Pharma.
PY - 2008
Y1 - 2008
N2 - Background: Although epilepsy is relatively common, only a limited number of specialized epilepsy centers exist in the United States. Therefore, epilepsy diagnosis and management frequently occur in the community setting. This can complicate patient management and suboptimal care is a potential concern. Delayed recognition and inadequate treatment increase the risk of subsequent seizures, brain damage, disability, and death from seizure-related injuries. To identify core elements of epilepsy management that should be offered to all patients, the Leadership in Epilepsy, Advocacy, and Development (LEAD) faculty assessed current practical issues and identified practices to improve patient care and outcomes. Scope: This paper presents a consensus opinion formed from a survey of 26 current LEAD faculty members, who answered 105 questions about epilepsy diagnosis and patient evaluation, treatment decisions, lifelong monitoring, and the management of special patient subgroups. Consensus agreement was concluded when ≥50% of the faculty provided the same answer. The results were compiled and areas of consensus are included in this report. The recommendations provided in this commentary are limited by the scope of the survey. Findings: Consensus was reached on several minimum standard patient management practices. Primary among these minimum standards of care is the need for diagnosis including a detailed medical history, neurological examination, discussions with caregivers, and diagnostic tests including electroencephalograms and magnetic resonance imaging. As the overall goals of therapy include seizure freedom, minimizing side effects, and improving quality of life and long-term safety, therapy decisions should consider parameters that affect these goals, including potential adverse effects of therapy. Antiepileptic drug selection should consider coexisting conditions for possible exacerbation of disease and potential drug-drug interactions. Conclusions: The core elements of epilepsy management identified here suggest minimum standards that can be used across all settings to improve consistency and quality of epilepsy diagnosis and care.
AB - Background: Although epilepsy is relatively common, only a limited number of specialized epilepsy centers exist in the United States. Therefore, epilepsy diagnosis and management frequently occur in the community setting. This can complicate patient management and suboptimal care is a potential concern. Delayed recognition and inadequate treatment increase the risk of subsequent seizures, brain damage, disability, and death from seizure-related injuries. To identify core elements of epilepsy management that should be offered to all patients, the Leadership in Epilepsy, Advocacy, and Development (LEAD) faculty assessed current practical issues and identified practices to improve patient care and outcomes. Scope: This paper presents a consensus opinion formed from a survey of 26 current LEAD faculty members, who answered 105 questions about epilepsy diagnosis and patient evaluation, treatment decisions, lifelong monitoring, and the management of special patient subgroups. Consensus agreement was concluded when ≥50% of the faculty provided the same answer. The results were compiled and areas of consensus are included in this report. The recommendations provided in this commentary are limited by the scope of the survey. Findings: Consensus was reached on several minimum standard patient management practices. Primary among these minimum standards of care is the need for diagnosis including a detailed medical history, neurological examination, discussions with caregivers, and diagnostic tests including electroencephalograms and magnetic resonance imaging. As the overall goals of therapy include seizure freedom, minimizing side effects, and improving quality of life and long-term safety, therapy decisions should consider parameters that affect these goals, including potential adverse effects of therapy. Antiepileptic drug selection should consider coexisting conditions for possible exacerbation of disease and potential drug-drug interactions. Conclusions: The core elements of epilepsy management identified here suggest minimum standards that can be used across all settings to improve consistency and quality of epilepsy diagnosis and care.
KW - Consensus development
KW - Disease management
KW - Epilepsy
KW - Long-term care
KW - Practice recommendations
UR - http://www.scopus.com/inward/record.url?scp=62349131524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=62349131524&partnerID=8YFLogxK
U2 - 10.1185/03007990802561148
DO - 10.1185/03007990802561148
M3 - Comment/debate
C2 - 19032128
AN - SCOPUS:62349131524
SN - 0300-7995
VL - 24
SP - 3463
EP - 3477
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
IS - 12
ER -